CBPHFCLOVER BIOPHARMACEUTICALS LTD.

About CLOVER BIOPHARMACEUTICALS LTD. (CBPHF)

CLOVER BIOPHARMACEUTICALS LTD. (CBPHF) is a company headquartered in Shanghai, China whose shares trade over-the-counter on the Pink tier.

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs.

CBPHF key facts

Ticker symbol

CBPHF

Market tier

Pink

Headquarters

Shanghai, China

Country of incorporation

KY

Year of incorporation

2018

Shares outstanding

1,253,673,382

Reporting standard

International Reporting: Hong Kong Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Explore more: Pink stocks · OTC stocks starting with C